跳至主要内容
临床试验/NCT02823509
NCT02823509已完成不适用

Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose.

Bayer0 个研究点目标入组 10 人开始时间: 2015年12月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
10
主要终点
Minimal Erythema Dose (MED)

研究概览

简要总结

To evaluate the Sun Protection Factor efficacy on human skin.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Fitzpatrick Skin Type l, ll and/or lll for UVB testing.
  • Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
  • Male and female
  • Aged between 18-70 years old.
  • Good health as determined from the HRL SHF
  • Signed and dated Informed Consent Form
  • Signed and dated HIPAA Form
  • An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose)

排除标准

  • Subjects on test at any other research laboratory or clinic.
  • Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
  • Pre-existing dermatologic conditions which have been dianoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
  • Pre-existing other medical conditions (e.g. adult asthma. diabetes).
  • Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
  • Treatment with antibiotics within two weeks prior to initiation of the test.
  • Chronic medication which could affect the results of the study.
  • Known pregnant or nursing women.

研究组 & 干预措施

Arm 1

Experimental

Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.

干预措施: Coppertone (BAY 987517) (Drug)

结局指标

主要结局

Minimal Erythema Dose (MED)

时间窗: Up to 15 minutes

Minimal Persistent Pigment Darkening Dose (MPPD)

时间窗: Up to 15 minutes

次要结局

未报告次要终点

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验

Sun Protection Factor Assay | 临床试验